Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KiroVax in Progressive/Refractory Solid Malignancies
NCT02224599Phase 2Terminated
- Sponsor
- Kiromic BioPharma, Inc.
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of KiroVax in Solid malignancy, sponsored by Kiromic BioPharma, Inc.. Started Jul 2017; status: terminated.
02
Drugs
KiroVax
03
Conditions
Solid malignancy
Beyond the preview
Go deeper on NCT02224599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224599.